Subcutaneous immunotherapy with aeroallergens - evaluation of adherence in real life by Lourenço, Tatiana et al.
O R I G I N A L   A R T I C L E Eur Ann AllErgy Clin immunol Vol 52, N.2, 84-90, 2020
t. loureNço1, m. FerNaNDeS1,2, c. coutiNho1, a. loPeS1, a. SPíNola SaNtoS1, m. Neto1, 
m. Pereira BarBoSa1,3
Subcutaneous immunotherapy with aeroallergens - 
evaluation of adherence in real life
1Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, 
Lisboa, Portugal 
2Unidade de Imunoalergologia, Hospital Dr. Nélio Mendonça, SESARAM, EPE, Funchal, Portugal
3Clínica Universitária de Imunoalergologia, Faculdade Medicina da Universidade de Lisboa, Lisboa, Portugal
Key words
allergy; allergic respiratory diseases; 




Serviço de Imunoalergologia 
Hospital de Santa Maria
Centro Hospitalar Universitário de Lisboa 
Norte (CHULN)
Avenida prof. Egas Moniz s/n
1649-035 Lisboa, Portugal
Phone: +351 21 780 5000





Introduction. Adherence in allergen immunotherapy is crucial for its efficacy. At 
least 3 years of treatment are recommended for achieving a long-term modifying effect. 
Objectives. To assess patient’s adherence and to identify determinant factors for allergen 
subcutaneous immunotherapy (SCIT) suspension in patients with respiratory allergy. 
Methods. Retrospective analysis of the medical record of patients submitted to SCIT 
between January 2013 and December 2016 in our Department. Results. 323 patients 
were included: 52% female; mean age 30 ± 13 years; average treatment time 19 ± 13 
months. 52 patients (16%) stopped SCIT: 54% female; mean age 30 ± 9 years; average 
treatment time 12 ± 6 months; 67% dropped the treatment during the 1st year, 27% 
in the 2nd and 6% during the 3rd year of treatment. Adherence rate determined was 
77%. The most frequent reasons for withdrawal were due to economic reasons (47.9%), 
followed by patients’ perception of no clinical improvement (23%) and change to sublin-
gual immunotherapy (11.6%). Conclusions. Adherence rate in our study was 77%. 
Economic reasons were the main cause of abandonment in the first year, while the per-
ception of non-improvement was the main reason for abandonment in subsequent years. 
Adequate information on SCIT prescribing and rigorous monitoring of patients during 
the treatment can improve adherence.
onset of asthma in patients with rhinitis or the appearance of 
new sensitizations (3). Subcutaneous administration is the main 
form of immunotherapy with aeroallergens because of its higher 
effectiveness (4). However, this treatment also has disadvantag-
es: the administration can be painful and it is associated with a 
higher risk of systemic reactions. Moreover, it is a time-consum-
ing procedure, due to the need for supervised administration by 
a trained health care professional in a setting with conditions for 
treating systemic reactions.
Adherence represents the most critical issue and it is essential for 
achieving good results. Poor adherence to immunotherapy leads 
to a decrease in treatment benefits that can potentially lead to 
an increase of morbidity (5). A minimum duration of 3-years 
of subcutaneous immunotherapy (SCIT), with an optimized 
Introduction
Allergic respiratory diseases, namely rhinitis and asthma, are a 
major public health problem. Asthma affects an estimated 300 
million individuals (1) and allergic rhinitis affects 10 to 40% of 
the population worldwide (2). These diseases are known to reduce 
the overall quality of life as well as to increase school and work ab-
senteeism and medical costs (2). Therefore, the correct treatment 
with adequate control of these diseases is very important.
The key points of the treatment of allergic respiratory diseases 
are patient education, allergen avoidance and pharmacological 
therapy (1,2). Allergen immunotherapy has shown to modify 
the natural history of allergic disease, maintaining beneficial ef-
fects even after its cessation and the possibility to prevent the 
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dosing schedule, is required to achieve an adequate clinical and 
immunological response and long-term efficacy (6). 
Adherence can be divided in three different stages: initiation 
(acceptance), implementation (compliance) and persistence 
(5). In this study we defined adherence as the accomplish-
ment of at least three complete years of SCIT. Although there 
is no consensus regarding what an acceptable adherence rate 
is, most researchers consider an adherence rate greater than 
80% to be adequate (5,7). In clinical trials the reported ad-
herence rate is around 80-90% and it is more variable in re-
al-world studies, ranging from 23-88% in adults and 16-89% 
in children (5).
The reasons for a poor adherence to SCIT may be related to the 
patient, disease, treatment or healthcare system (5). The iden-
tification of these factors can increase the success of immuno-
therapy. The most common factors associated with a poor ad-
herence to SCIT are: the patient´s knowledge of his/her disease 
and treatment conditions and benefits, route of administration, 
treatment inconvenience and costs and side effects (5).
The aim of this study was to evaluate SCIT adherence in pa-
tients with allergic rhinitis and/or asthma and to determine the 
factors that affect adherence to in real-life conditions.
Material and methods
Population and study design 
A retrospective analysis of the medical and nursing records of 
631 patients submitted to SCIT between January 2013 and 
December 2016 in our Immunotherapy Center, Allergy and 
Clinical Immunology Outpatient Clinic of Hospital de Santa 
Maria, Centro Hospitalar Universitário de Lisboa Norte, was 
performed. Patients’ age, gender, allergic disease diagnosis (rhi-
nitis and/or asthma; eczema; conjunctivitis; food allergy), SCIT 
composition, date of initiation and SCIT administration sched-
ule were registered and evaluated. The reasons to stop SCIT were 
also analyzed and evaluated. Switching to sublingual route of im-
munotherapy was considered a reason of SCIT dropout, once 
the aim of this study was to specifically evaluate adherence to 
the subcutaneous route and determine the factors that affect it.
 Patients who lacked clinical information about SCIT compo-
sition or administration (n = 211), were contacted by letter re-
questing SCIT administration protocol information, with very 
poor response (response rate 16%). Patients that sent the SCIT 
administration protocol and had dropout SCIT were contacted 
again, by call and were asked about dropout reasons.
Patients were excluded from the study if SCIT was administered 
in another facility (n = 131) or if there was missing information 
in their medical records concerning SCIT administration, name-
ly SCIT composition, date of initiation and SCIT administra-
tion schedule (n = 177) (figure 1). This lack of parameters is due 
to absence of electronic clinical records before 2012/2013 and 
the impossibility to get access to written medical information.
The diagnosis and treatment of allergic rhinitis and asthma were 
appropriate according to current guidelines, Allergic Rhinitis 
and its Impact on Asthma (ARIA) (8) and Global Initiative for 
Asthma (GINA) (1). Skin prick tests with Roxall® extracts and/
or serum specific IgE tests using ImmunoCAP system® (Ter-
moFisher scientific; Uppsala, Sweden) were conducted. All pa-
tients had positive skin prick tests and/or specific IgE tests > 
0.70 kU/L, and a correlation between these results and their 
symptoms was found. SCIT was initiated in patients with aller-
gic symptoms despite being under medical treatment. SCIT was 
chosen considering the results of skin prick tests and/or specific 
IgE tests to house dust mites, storage mites, pollens (grass, Pa-
rietaria, olive tree and Artemisia) and cat epithelium or extract 
associations (mites and pollens). The route of therapy (subcu-
taneous) was prescribed taking into consideration the patient’s 
preference, allergic symptoms and personal concerns.
A written informed consent was obtained from all patients and/
or their legal representatives before initiating SCIT. 
The maintenance dose was administered at 4-6-week intervals 
over a period of 3 to 5 years. All injections were administered 
by trained nurses with supervision of the allergist in the Immu-
notherapy Center, equipped with material for treating systemic 
reactions. All patients were evaluated before and 30 minutes af-
ter the SCIT administration. 
Adherence was determined as the accomplishment of three years 
of SCIT. The patients who dropped SCIT before this time were 
considered as non-adherent; the patients that continued the 
treatment were considered as adherent. To calculate adherence 
rate, only patients who started SCIT in 2013 were considered in 
order to have completed the recommended three years of treat-
ment, since it is the minimum to be considered compliant.
Data were anonymized, and their confidentiality guaranteed, 
and this study protocol was approved by the Ethical Board of 
Centro Hospitalar Universitário de Lisboa Norte.
Descriptive and statistical analysis
As previously mentioned, the main objective of this study was 
to assess and identify the main causes behind treatment discon-
tinuation. According to our objectives, we analyzed the group 
of patients who stopped SCIT and evaluated the causes that 
contributed to the suspension of SCIT using descriptive statis-
tics. For the descriptive analysis, categorical variables were giv-
en as numbers and percentages, and continuous variables were 
presented using mean, standard deviation, median, interquartile 
range (IQR) and minimum and maximum values. 
Statistical analyses were performed using version 24 of SPSS 
software for Windows (SPSS Inc., Chicago, Ill). Mann-Whit-
ney U and Kruskal-Wallis tests were used to compare differ-
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ences between groups and p value < 0.05 was considered sta-
tistically significant.
Results
From a total of 631 patients under SCIT during the study peri-
od, 323 patients met the inclusion criteria and 308 were exclud-
ed due to data unavailability.
According to the demographic data (table I), there was a pre-
dominance of female gender (167, 52%), mean age of the pa-
tients was 30 ± 13 years (minimum 7, maximum 65, median 
27). The age group of 18 to 30 years was the most prevalent 
with 45% (n = 145) and the group older than 50 years was the 
least prevalent with 7.1% (n = 23).
Regarding the allergen used in SCIT, we observed a predom-
inance of mite allergen (233, 72%). More information about 
SCIT composition is detailed in table I.
The diagnosis of patients submitted to SCIT was also evaluated 
and is provided in table I. All patients had allergic respiratory 
disease, with rhinitis being the most frequent diagnosis (313, 
97%) followed by asthma (145, 45%), about 40% of patients 
had concomitant asthma and rhinitis. The average treatment 
duration was 19 ± 13 months (maximum 58 months; mini-
mum 1 month). Most patients (70.8%) were in the first 2 years 
of SCIT and 17.7% completed at least 3 years of treatment. We 
also evaluated the number of patients by year of treatment: first 
year 132, 40.8%; second year 97, 30%; third year 37, 11.5%; 
fourth year 38, 11.8%; fifth year 19, 5.9%.
When comparing the patients who dropped SCIT without 
medical indication with those who completed the treatment 
(i.e. adherent group), no statistical differences were found re-
garding age, gender, clinical diagnosis and allergen extract (ta-
ble I). Table I shows the clinical and demographic comparison 
between the 2 groups (adherent and non-adherent patients).
Adherence was determined at the end of 3 years of SCIT treat-
ment. Fifty-two patients (16%) stopped SCIT without medical 
indication before the recommended time. In the group of pa-
tients who abandoned SCIT (i.e. non-adherent patients), there 
was a slight predominance of female gender (28, 54%), mean 
age 30 ± 9 years (minimum 14, maximum 48, median 28). 
Figure 1 - Study design and flow chart.
Initial: n=631 patients
EXCLUSION CRITERIA
SCIT administration in another facility
n=131 patients
EXCLUSION CRITERIA





n=289 patients - information in 
medical records
n=211 patients - lack of information 
in medical records
SCIT administration protocol requested
Final: n=323 patients
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The most prevalent age group was from 18 to 30 years old 
(54%) and the least prevalent age group was from 7 to 17 years 
old (7.7%). Regarding the immunotherapy composition, SCIT 
suspension for mites was predominant (73%, 16.3% of total 
SCIT for mites) followed by pollens (32.6%, 13.6% of total 
SCIT for pollens). The average treatment duration was 12 ± 6 
months (maximum 27 months; minimum 4 months). 
In order to calculate adherence rate, only patients who started 
SCIT in 2013 were considered in order to have completed the 
recommended three years of treatment, since it is the minimum 
to be considered compliant. Fifty-seven patients started SCIT in 
this year and 13 stopped it before completing 3 years of treat-
ment, corresponding to an adherence rate of 77%.
Most patients (67%) abandoned SCIT during the first year, 
27% in the second and 6% during the third year of treatment. 
The main reasons for abandoning SCIT without medical indi-
cation are presented in table II. 
Economic reasons were the most frequent factor reported, 
accounting for almost half of the treatment abandonment 
(47.9%). Twenty-three percent referred the absence of clinical 
improvement and around 12% switched to sublingual immu-
notherapy. Personal issues such as relocation, support to fam-
ily and professional reasons resulted in 7.7% of suspensions; 
adverse reactions, namely large recurrent local reactions mo-
tivated 3.9% of the SCIT suspension. Two patients (3.9%) 
stopped SCIT because they were diagnosed with other medical 
conditions (neoplasm). Pregnancy was the reason behind the 
withdrawal of 2% of patients; in this case, SCIT abandonment 
was a patient’s choice.
When analyzed the main causes by year, results have shown that 
the most frequent cause of suspension in the first year was due 
to economic reasons (21/35, 60%), and the perception of no 
improvement was the most frequent reason in the following 
years (7/17, 41%).
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The heterogeneity of the results found in literature can be ex-
plained by the differences existing between the studies method-
ologies, populations, countries, allergen composition vaccines, 
treatment schedules, immunotherapy cost and funding. The 
concept of adherence is also variable; in some studies it is de-
fined as missed doses of SCIT, while in others as stopping SCIT 
without medical approval.
When compared with previous published data, and accord-
ing with the definition of good adherence, our adherence rate 
can be considered as acceptable. These good results can be ex-
plained by the existence of an Immunotherapy Center in our 
Outpatient Clinic where we try to promote a close and genuine 
patient-physician relation. There is always a support physician 
for SCIT administration that facilitates physician-patient com-
munication, helping with any problem or doubt, namely ad-
dressing questions about the treatment itself, adverse reactions 
or any other patient’s doubt. We provide a weekly schedule 
with extended hours in order to offer several options to SCIT 
administration and try not to interfere with regular working 
hours. We also have a direct phone number that patients can 
call and contact us easily. Frequent visits at our Center permit 
that our professionals (nurses and physicians) can enhance ad-
herence during the visits, offering a continuous education on 
SCIT principles.
No statistical differences were found in our study between ad-
herent and non-adherent groups in what concerns age, gender, 
clinical diagnosis or allergenic composition of the SCIT. Al-
though it was not significant, we observed a decrease of SCIT 
Table II - Reasons for subcutaneous immunotherapy withdrawal.
Reasons for SCIT 
withdrawal
Non-adherent patients (n = 52)
1st 
year
n = 35 
2nd 
year






economic reasons 21 4 0 25 (47.9)
no clinical improvement 5 7 0 12 (23)
switch to sublingual 
immunotherapy  
4 2 0 6 (11.6)
personal issues 2 0 2 4 (7.7)
adverse reactions 2 0 0 2 (3.9)
medical illness 0 1 1 2 (3.9)
pregnancy 1 0 0 1 (2)
Table III - Adherence to treatment in subcutaneous immunotherapy studies.
Study sample (n) age group study duration (follow-up) adherence rate (%)
Cohn et al., 1993 (9) 217 adults 4 years 50
Lower et al., 1993 (10) 315 children 4 years 56
Donahue et al., 1999(11) 603 children and adults 4 years 33
Rhodes, 1999 (12) 1033 adults 3 years 88
More et al., 2002 (13) 381 children and adults 3 years 77
Pajno et al., 2005 (14) 1886 children 3 years 89
Hankin et al., 2008 (15) 520 children 3 years 47 (1st year)
16 (3rd year)
Hsu et al., 2012 (16) 139 adults 4 years 55
Guedechea-Sola et al., 2013 (17) 156 adults 5 years 63
Kiel et al., 2013 (18) 2796 adults 3 years 23
Silva et al., 2014 (19) 122 children and adults 4 years 54
Gelincik et al., 2017 (20) 204 adults 3 years 73
Lemberg et al., 2017 (21) 207 children and adults 3 years 68
Yang et al., 2018 (22) 311 children and adults 3 years 64.6
Tat, 2018 (23) 95 adults 3 years 65
Lee et al., 2019 (24) 1162 children and adults 3 years 80
Discussion
In our real-life study, the adherence rate was 77%. In total, 52 
(16%) patients dropped out: 35 patients (67.3%) in year 1, 14 
(27%) in year 2, and 3 (5.7%) in year 3. Reviewing the litera-
ture, we find that reported SCIT adherence rates are very vari-
able, both in percentage as follow up duration (3 and 4 years). 
The adherence rate of previous studies is summarized in table 
III and ranges between 23-88%. In most studies, the adherence 
rate is < 70%, lower than the rate shown in our work. 
89Subcutaneous immunotherapy with aeroallergens - evaluation of adherence in real life
suspension in younger patients. In literature, results regarding 
demographic and clinical data are also very variable. Tat also has 
not found differences in age or gender between the two groups 
(23). Rhodes found a significant correlation between age and 
gender: non-adherent patients were younger than adherent and 
males were more frequently non-adherents than females (12). 
More et al. confirmed Rhodes findings in what concerns age 
(13). On the other hand, Yang et al. concluded that children 
had higher adherence to SCIT than adults and did not found 
any other correlation with gender (22). Gelincik et al. conclud-
ed that adherence was higher in female patients. Age, clinical 
diagnosis and the type of allergen extract used for SCIT did not 
influence the adherence rate (20). Donahue et al. reported a 
higher adherence in patients with both asthma and rhinitis then 
in those with either of them (11). However, More et al. and 
Yang et al. have not found a correlation between adherence and 
kind of respiratory disease (13, 22).
Lemberg et al. concluded that patients who adhere to immuno-
therapy in the first year of the treatment are more likely to com-
plete it (21). Their conclusion is in agreement with our data, 
where more than half of the non-adherent patients discontinued 
the treatment during the first year.
In order to improve adherence to treatment, it becomes particu-
larly important to identify patients who are likely to be non-ad-
herent and find out the reasons for stopping the treatment. The 
reasons for SCIT suspension are also variable among the liter-
ature; there is a lot of heterogeneity and the identified factors 
vary depending on the countries and populations involved.
In our study, we evaluated not only the main reasons for SCIT 
suspension, but we also evaluated it in separate years since the 
beginning of SCIT. Economic reasons were the main cause of 
drop-outs, responsible for 47.9% of immunotherapy suspen-
sion in a global way and for 60% of SCIT suspension in the 
first year. These results are in agreement with another study 
conducted in the north of Portugal in 2014, which reported 
the treatment cost as the main reason for abandoning SCIT in 
59% of participants (19). To our knowledge, these are the only 
studies evaluating the reasons for SCIT non-adherence in Por-
tugal, where SCIT cost ranges from 250 - 350 €/year, without 
reimbursement in most cases. This amount does not include 
the expenses related to the administration of the treatment and 
transportation to the hospital. Similarly, an Italian study con-
ducted in 2005 also concluded that the cost of SCIT was the 
most common cause of treatment withdrawal, responsible for 
39.6% of SCIT drop-outs (14). In 2011, Vaswani et al. reported 
a rate of 40% of suspension due to SCIT costs, especially inad-
equate or nonexistent insurance coverage (25). In his study, Tat 
also concluded that a main reason for SCIT suspension was the 
delayed reimbursement by health insurance (23). 
Another important adherence factor is the patient’s perception 
of clinical improvement. It is associated with his/her knowledge 
of treatment and the expectation of the time from initiation to 
symptom relief and the degree of improvement to be achieved. 
In our study, individual perception of absence of clinical im-
provement was the second leading cause of treatment withdraw-
al, resulting in approximately 23% of treatment discontinuation 
and being the main reason of suspension during the second and 
third year of SCIT. Gelincik et al. in their study referred the lack 
of efficacy as a major cause of SCIT cessation with a percentage 
of 66.7% (20). Silva et al. found a percentage of almost 27% 
due to lack of efficacy (19). Yang et al. described a discontinu-
ation rate of 25.5% secondary to treatment inefficacy (second 
more frequent cause in their study) (19). Tat described a with-
drawal of 14.8% of patients secondary to lack of efficacy (23). 
In our study, 11.6% of patients preferred a change to sublingual 
immunotherapy due to SCIT inconvenience, namely, route of 
administration and need of monthly hospital visits. Although 
it was not the main reason for suspension of SCIT in the pres-
ent study, treatment inconvenience is described in many studies 
as the main reason for treatment abandonment (9,12,16) with 
proportions ranging from 35 to 65%. Tat described a percent-
age similar to ours: 14.8% (23). 
It is crucial to ensure a high adherence rate to SCIT, prior to its 
prescription, to inform patients about goals, risks, duration of 
treatment, direct and indirect costs and potential inconvenience 
related with the treatment (travel to appointments, skipping 
work). These aspects are crucial for patient’s involvement in the 
decision to initiate SCIT. Frequently, the patient’s expectations 
do not coincide with those of the physician. Sade et al. con-
cluded that 39% of patients under SCIT expected full recovery, 
35% expected some improvement, 16% expected prevention 
of the development of new allergies and 10% expected protec-
tion against the onset of asthma. In what concerns the patient’s 
knowledge about the duration of treatment, 60% were unaware 
of the optimal duration and only 10% were expecting several 
years of therapy. These data indicate that patients were not in-
formed about the principles of treatment with SCIT. Another 
conclusion was that patients who initiated treatment within the 
previous 6 months were more informed about it that patients 
receiving therapy for a longer period of time (26), reinforcing 
the necessity to evaluate these patients periodically. 
To our knowledge, this is the second study made in Portugal 
on SCIT adherence, namely determination of the adherence 
rate and the reasons responsible for its suspension. Our study 
has a large sample with 323 patients. Concerning suspension 
factors, we evaluated these factors in a global manner and also 
performed an individualized analysis per year, aiming to identify 
and group the main causes of SCIT withdrawal and trying to 
be more attentive in these aspects, preventing SCIT suspension.
Limitations 
The study design may limit the results: it is a retrospective 
study performed in one center; there was an exclusion of al-
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most half of the total population due to lack of clinical infor-
mation about SCIT administration. Moreover, our definition 
of adherence may differ from those of other studies, which 
can lead to some difficulty in comparing factors associated 
with immunotherapy adherence between the reported results. 
Also, this study does not consider failures / inadequate dos-
es of allergen in SCIT administration as non-compliance of 
treatment.
More evidence is needed from larger samples in prospective 
studies, where we can get more detailed information address-
ing all dimensions of adherence. In addition, the definition of 
adherence and non-adherence to immunotherapy should be ad-
dressed in future immunotherapy guidelines.
Conclusions
The adherence rate in our study can be considered high when 
compared with other real-world rates, while economic reasons, 
followed by lack of efficacy and SCIT inconvenience were the 
main causes for patient’s non-adherence. Informing the patients 
about the progress of the allergic disease and immunotherapy pro-
gram may help to improve compliance. Well-informed patients 
are less likely to drop SCIT, once they can follow a long-lasting 
treatment which takes to a gradual symptom improvement.
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